Physician profile
Jorge A Quel
NPI 1700915311
$5,427.42
in general payments reported to CMS, 2019-2025
22 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $24.19 · 2021: $129 · 2022: $671 · 2023: $1,069 · 2024: $1,450 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,889 · Education: $26.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,889.19 |
| Education | $26.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,467.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,260.89 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $543.21 | 2022-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $362.72 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $282.78 | 2019-2025 | |
| Optinose US, INC. | $276.38 | 2019-2022 | |
| Amgen INC. | $187.62 | 2023-2025 | Tezspire |
| Alk-Abello, INC | $148.48 | 2019-2024 | Odactra, Grastek, Ragwitek |
| Biocryst US Sales Co., LLC | $132.31 | 2023-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.18 | 2019 | |
| Octapharma USA, INC. | $129.33 | 2024-2025 | Cutaquig |
| Blueprint Medicines Corporation | $97.75 | 2024-2025 | Ayvakit |
| Grifols USA, LLC | $96.65 | 2024-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $67.89 | 2025 | Neffy |
| Genentech USA, INC. | $49.00 | 2020-2023 | Xolair |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.89 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.40 | 2021-2025 | Cuvitru |
| Phadia US INC. | $36.06 | 2024 | Immunocap |
| Pfizer INC. | $26.82 | 2024 | |
| Horizon Therapeutics Plc | $20.71 | 2019 | |
| X4 Pharmaceuticals, INC. | $19.33 | 2025 | Xolremdi |
| Organon LLC | $6.35 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Quel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.